2012 Canadian Guidelines for the Diagnosis and Management of Fibromyalgia Syndrome: Executive Summary

Simple item page
dc.contributor.authorFitzcharles, Mary-Ann
dc.contributor.authorSte-Marie, Peter A
dc.contributor.authorGoldenberg, Don L
dc.contributor.authorPereira, John X
dc.contributor.authorAbbey, Susan
dc.contributor.authorChoinière, Manon
dc.contributor.authorKo, Gordon
dc.contributor.authorMoulin, Dwight E
dc.contributor.authorPanopalis, Pantelis
dc.contributor.authorProulx, Johanne
dc.contributor.authorShir, Yoram
dc.contributor.authorthe National Fibromyalgia Guideline Advisory Panel,
dc.date.accessioned2018-09-27T11:44:57Z
dc.date.available2018-09-27T11:44:57Z
dc.date.issued2013-01-01
dc.date.updated2018-09-27T11:44:57Z
dc.description.abstractBACKGROUND: Recent neurophysiological evidence attests to the validity of fibromyalgia (FM), a chronic pain condition that affects >2% of the population.OBJECTIVES: To present the evidence-based guidelines for the diagnosis, management and patient trajectory of individuals with FM.METHODS: A needs assessment following consultation with diverse health care professionals identified questions pertinent to various aspects of FM. A literature search identified the evidence available to address these questions; evidence was graded according to the standards of the Oxford Centre for Evidence-Based Medicine. Drafted recommendations were appraised by an advisory panel to reflect meaningful clinical practice.RESULTS: The present recommendations incorporate the new clinical concepts of FM as a clinical construct without any defining physical abnormality or biological marker, characterized by fluctuating, diffuse body pain and the frequent symptoms of sleep disturbance, fatigue, mood and cognitive changes. In the absence of a defining cause or cure, treatment objectives should be patient-tailored and symptom-based, aimed at reducing global complaints and enhancing function. Healthy lifestyle practices with active patient participation in health care forms the cornerstone of care. Multimodal management may include nonpharmacological and pharmacological strategies, although it must be acknowledged that pharmacological treatments provide only modest benefit. Maintenance of function and retention in the workforce is encouraged.CONCLUSIONS: The new Canadian guidelines for the treatment of FM should provide health professionals with confidence in the complete care of these patients and improve clinical outcomes.
dc.description.versionPeer Reviewed
dc.identifier.citationMary-Ann Fitzcharles, Peter A Ste-Marie, Don L Goldenberg, et al., “2012 Canadian Guidelines for the Diagnosis and Management of Fibromyalgia Syndrome: Executive Summary,” Pain Research and Management, vol. 18, no. 3, pp. 119-126, 2013. doi:10.1155/2013/918216
dc.identifier.doihttps://doi.org/10.1155/2013/918216
dc.identifier.urihttp://hdl.handle.net/1880/108298
dc.identifier.urihttps://doi.org/10.11575/PRISM/44427
dc.language.rfc3066en
dc.rights.holderCopyright © 2013 Hindawi Publishing Corporation. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
dc.title2012 Canadian Guidelines for the Diagnosis and Management of Fibromyalgia Syndrome: Executive Summary
dc.typeJournal Article
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
PRM.2013.918216.pdf
Size:
526.6 KB
Format:
Adobe Portable Document Format
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
0 B
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Open Access Publications